AppSoft Technologies $ASFT Going After Slice of $1 Billion E-Sports Market
26 Feb
2018
Written by Mike Elliott

AppSoft Technologies $ASFT Going After Slice of $1 Billion E-Sports Market »

AppSoft Technologies, Inc. develops, publishes and markets mobile software applications for smartphones and tablet devices ("Apps").

Read more...
Pacific Green Technologies $PGTK Set For Break Out As New Emissions Rules For Cargo Ships Set
20 Feb
2018
Written by Mike Elliott

Pacific Green Technologies $PGTK Set For Break Out As New Emissions Rules For Cargo Ships Set »

In this episode, Scott discusses the company's progress as well as the market need for Pacific Green's patented Envi-Marine emissions control system which has several competitive advantages in this rapidly growing industry.

Read more...
Hemispherx $HEB Ampligen May Offer Solution for Universal Flu Vaccine
20 Feb
2018
Written by Mike Elliott

Hemispherx $HEB Ampligen May Offer Solution for Universal Flu Vaccine »

In this episode, Mr. Equels discusses the $500+ million market opportunity for Ampligen the Only Late Stage ME/CFS Candidate in the U.S. as well as the company's ongoing commitment to immuno-oncology.

Read more...
Nano Dimension $NNDM Elevates Industry 4.0 with 3D Printing of Smart Products
6 Feb
2018
Written by Mike Elliott

Nano Dimension $NNDM Elevates Industry 4.0 with 3D Printing of Smart Products »

Nano Dimension is a leading additive manufacturing technology company. They are disrupting, reshaping and defining the future of how smart products are made.

Read more...
Blue Sky Uranium (OTC:BKUCF) CEO Discusses Positive Results from Amarillo Grande Project
5 Feb
2018
Written by Mike Elliott

Blue Sky Uranium (OTC:BKUCF) CEO Discusses Positive Results from Amarillo Grande Project »

In this episode of CEOLIVE.TV we are joined by Mr. Nikolaus Cacos, President and CEO of Blue Sky Uranium Corp., ticker CVE:BSK.

Read more...
Citius Pharmaceutical $CTXR Mino-Lok™ Phase 3 Clinical Trial Ready
5 Feb
2018
Written by Mike Elliott

Citius Pharmaceutical $CTXR Mino-Lok™ Phase 3 Clinical Trial Ready »

Citius is a specialty pharmaceutical company dedicated to the development and commercialization of unique therapeutic products in adjunctive cancer care with a focus on infectious diseases.

Read more...

Login

Lost your password?